Drugs targeting HER2 have shown excellent clinical efficacy over the 20 years, achieving one milestone after another in the field of cancer therapeutics. This article mainly introduces the development history […]
On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (Nerlynx, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer to […]